Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Equity Average (2016 - 2026)

Anika Therapeutics has reported Equity Average over the past 16 years, most recently at $138.7 million for Q1 2026.

  • Quarterly Equity Average fell 8.27% to $138.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $138.7 million through Mar 2026, down 8.27% year-over-year, with the annual reading at $148.7 million for FY2025, 18.78% down from the prior year.
  • Equity Average was $138.7 million for Q1 2026 at Anika Therapeutics, down from $145.1 million in the prior quarter.
  • Over five years, Equity Average peaked at $286.4 million in Q1 2022 and troughed at $138.7 million in Q1 2026.
  • The 5-year median for Equity Average is $210.4 million (2024), against an average of $219.2 million.
  • Year-over-year, Equity Average increased 4.34% in 2022 and then tumbled 30.84% in 2024.
  • A 5-year view of Equity Average shows it stood at $285.2 million in 2022, then decreased by 15.38% to $241.4 million in 2023, then tumbled by 30.84% to $166.9 million in 2024, then dropped by 13.05% to $145.1 million in 2025, then dropped by 4.45% to $138.7 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Equity Average are $138.7 million (Q1 2026), $145.1 million (Q4 2025), and $147.2 million (Q3 2025).